Bozdag, G. et al. The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis. Hum. Reprod. 31(12), 2841–2855 (2016).
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81(1), 19–25 (2004).
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19(1), 41–47 (2004).
Glueck, C. J. & Goldenberg, N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism 92, 108–120 (2019).
Hudecova, M. et al. Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome–a long term follow-up. Hum. Reprod. 26(6), 1462–1468 (2011).
Celik, C. et al. Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: A controlled follow-up study. Fertil. Steril. 101(4), 1123–8.e1 (2014).
Kakoly, N. S. et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: A systematic review and meta-regression. Hum. Reprod. Update 24(4), 455–467 (2018).
Ollila, M. M. et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective, population-based cohort study. Hum. Reprod. 32(2), 423–431 (2017).
Wekker, V. et al. Long-term cardiometabolic disease risk in women with PCOS: A systematic review and meta-analysis. Hum. Reprod. Update 26(6), 942–960 (2020).
Yin, X. et al. The mental health of women with polycystic ovary syndrome: A systematic review and meta-analysis. Arch. Womens Ment. Health 24(1), 11–27 (2021).
Ahmadi, M. et al. Mental and personality disorders in infertile women with polycystic ovary: A case-control study. Afr. Health Sci. 20(3), 1241–1249 (2020).
Chaudhari, A. P., Mazumdar, K. & Mehta, P. D. Anxiety, depression, and quality of life in women with polycystic ovarian syndrome. Indian J. Psychol. Med. 40(3), 239–246 (2018).
Brutocao, C. et al. Psychiatric disorders in women with polycystic ovary syndrome: A systematic review and meta-analysis. Endocrine 62(2), 318–325 (2018).
Damone, A. L. et al. Depression, anxiety and perceived stress in women with and without PCOS: A community-based study. Psychol. Med. 49(9), 1510–1520 (2019).
Karjula, S. et al. Psychological distress is more prevalent in fertile age and premenopausal women With PCOS symptoms: 15-year follow-up. J. Clin. Endocrinol. Metab. 102(6), 1861–1869 (2017).
Baskind, N. E. & Balen, A. H. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome. Best Pract. Res. Clin. Obstet. Gynaecol. 37, 80–97 (2016).
Walters, K. A. et al. New perspectives on the pathogenesis of PCOS: Neuroendocrine origins. Trends Endocrinol. Metab. 29(12), 841–852 (2018).
Witchel, S. F. & Tena-Sempere, M. The Kiss1 system and polycystic ovary syndrome: Lessons from physiology and putative pathophysiologic implications. Fertil. Steril. 100(1), 12–22 (2013).
Dumesic, D. A. et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr. Rev. 36(5), 487–525 (2015).
Coutinho, E. A. & Kauffman, A. S. The role of the brain in the pathogenesis and physiology of polycystic ovary syndrome (PCOS). Med. Sci. 7(8), 84 (2019).
Hague, W. M. et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin. Endocrinol. 33(4), 501–510 (1990).
Wang, J. et al. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sci. 236, 116940 (2019).
Shorakae, S. et al. The emerging role of chronic low-grade inflammation in the pathophysiology of polycystic ovary syndrome. Semin. Reprod. Med. 33(4), 257–269 (2015).
Shorakae, S. et al. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin. Endocrinol. 89(5), 628–633 (2018).
Dag, Z. O. et al. Autonomic dysfunction in patients with polycystic ovary syndrome. Taiwan J. Obstet. Gynecol. 54(4), 381–384 (2015).
Velusami, D. & Sivasubramanian, S. Sympathovagal imbalance and neurophysiologic cognitive assessment using evoked potentials in polycystic ovary syndrome in young adolescents—a cross-sectional study. J. Basic Clin. Physiol. Pharmacol. 30(2), 233–237 (2018).
Li, W., Chen, Y. & Xu, L. Association of sympathetic nervous system activity with polycystic ovarian syndrome. Clin. Exp. Obstet. Gynecol. 41(5), 499–506 (2014).
Saranya, K. et al. Assessment of cardiovascular autonomic function in patients with polycystic ovary syndrome. J. Obstet. Gynaecol. Res. 40(1), 192–199 (2014).
Gibbons, C. H. Basics of autonomic nervous system function. Handb. Clin. Neurol. 160, 407–418 (2019).
Butt, M. F. et al. The anatomical basis for transcutaneous auricular vagus nerve stimulation. J. Anat. 236(4), 588–611 (2020).
Ondicova, K. & Mravec, B. Multilevel interactions between the sympathetic and parasympathetic nervous systems: A minireview. Endocr. Regul. 44(2), 69–75 (2010).
Farmer, A. D., Albu-Soda, A. & Aziz, Q. Vagus nerve stimulation in clinical practice. Br. J. Hosp. Med. 77(11), 645–651 (2016).
Mónica Brauer, M. & Smith, P. G. Estrogen and female reproductive tract innervation: Cellular and molecular mechanisms of autonomic neuroplasticity. Auton. Neurosci. 187, 1–17 (2015).
Gerendai, I. et al. Recent findings on the organization of central nervous system structures involved in the innervation of endocrine glands and other organs; observations obtained by the transneuronal viral double-labeling technique. Endocrine 36(2), 179–188 (2009).
Lara, H. E. et al. Activation of ovarian sympathetic nerves in polycystic ovary syndrome. Endocrinology 133(6), 2690–2695 (1993).
Barria, A. et al. Ovarian steroidal response to gonadotropins and beta-adrenergic stimulation is enhanced in polycystic ovary syndrome: Role of sympathetic innervation. Endocrinology 133(6), 2696–2703 (1993).
Lara, H. E. et al. An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology 141(3), 1059–1072 (2000).
Manni, L. et al. Ovarian expression of alpha (1)-and beta (2)-adrenoceptors and p75 neurotrophin receptors in rats with steroid-induced polycystic ovaries. Auton. Neurosci. 118(1–2), 79–87 (2005).
Dissen, G. A. et al. Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. Endocrinology 150(6), 2906–2914 (2009).
Figueroa, F. et al. Sympathetic innervation regulates macrophage activity in rats with polycystic ovary. J. Endocrinol. 238(1), 33–45 (2018).
Hashim, Z. H., Hamdan, F. B. & Al-Salihi, A. R. Autonomic dysfunction in women with polycystic ovary syndrome. Iran J. Reprod. Med. 13(1), 27–34 (2015).
Shorakae, S. et al. High-molecular-weight adiponectin is inversely associated with sympathetic activity in polycystic ovary syndrome. Fertil. Steril. 109(3), 532–539 (2018).
Sverrisdóttir, Y. B. et al. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?. Am. J. Physiol. Endocrinol. Metab. 294(3), E576–E581 (2008).
Lansdown, A. & Rees, D. A. The sympathetic nervous system in polycystic ovary syndrome: A novel therapeutic target?. Clin. Endocrinol. 77(6), 791–801 (2012).
Lanska, D. J. J. L. Corning and vagal nerve stimulation for seizures in the 1880s. Neurology 58(3), 452–459 (2002).
Wang, Y. et al. Vagus nerve stimulation in brain diseases: Therapeutic applications and biological mechanisms. Neurosci. Biobehav. Rev. 127, 37–53 (2021).
Johnson, R. L. & Wilson, C. G. A review of vagus nerve stimulation as a therapeutic intervention. J. Inflamm. Res. 11, 203–213 (2018).
Giordano, F. et al. Vagus nerve stimulation: Surgical technique of implantation and revision and related morbidity. Epilepsia 58(Suppl 1), 85–90 (2017).
Wang, Yu. et al. Transcutaneous auricular vagus nerve stimulation: From concept to application. Neurosci. Bull. 37(6), 853–862 (2021).
Borgmann, D. et al. Technical note: Modulation of fMRI brainstem responses by transcutaneous vagus nerve stimulation. Neuroimage 244, 118566 (2021).
Lewis, P. M. et al. Brain neuromodulation techniques: A review. Neuroscientist 22(4), 406–421 (2016).
Kaniusas, E. et al. Current directions in the auricular vagus nerve stimulation II—an engineering perspective. Front. Neurosci. 13, 772 (2019).
Nicholson, W. C. et al. The potential role of vagus-nerve stimulation in the treatment of HIV- associated depression: A review of literature. Neuropsychiatr. Dis. Treat. 13, 1677–1689 (2017).
Ben-Menachem, E. et al. Surgically implanted and non-invasive vagus nerve stimulation: A review of efficacy, safety and tolerability. Eur. J. Neurol. 22(9), 1260–1268 (2015).
Carandina, A. et al. Effects of transcutaneous auricular vagus nerve stimulation on cardiovascular autonomic control in health and disease. Auton. Neurosci. 236, 102893 (2021).
Snider, A. P. & Wood, J. R. Obesity induces ovarian inflammation and reduces oocyte quality. Reproduction 158(3), R79–R90 (2019).
Jin, P. & Xie, Y. Treatment strategies for women with polycystic ovary syndrome. Gynecol. Endocrinol. 34(4), 272–277 (2018).
de Lartigue, G. Role of the vagus nerve in the development and treatment of diet-induced obesity. J. Physiol. 594(20), 5791–5815 (2016).
Bodenlos, J. S. et al. Vagus nerve stimulation acutely alters food craving in adults with depression. Appetite 48(2), 145–153 (2007).
Burneo, J. G. et al. Weight loss associated with vagus nerve stimulation. Neurology 59(3), 463–464 (2002).
Pardo, J. V. et al. Weight loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: An observation. Int. J. Obes. 31(11), 1756–1759 (2007).
Bugajski, A. J. et al. Effect of long-term vagal stimulation on food intake and body weight during diet induced obesity in rats. J. Physiol. Pharmacol. 58(Suppl 1), 5–12 (2007).
Gil, K. et al. Physiological and morphological effects of long-term vagal stimulation in diet induced obesity in rats. J. Physiol. Pharmacol. 60(Suppl 3), 61–66 (2009).
Gil, K., Bugajski, A. & Thor, P. Electrical vagus nerve stimulation decreases food consumption and weight gain in rats fed a high-fat diet. J. Physiol. Pharmacol. 62, 637–646 (2011).
Gil, K. et al. Chronic vagus nerve stimulation reduces body fat, blood cholesterol and triglyceride levels in rats fed a high-fat diet. Folia Med. Cracov. 52(3–4), 79–96 (2012).
Dai, F., Yin, J. & Chen, J. D. Z. Effects and mechanisms of vagal nerve stimulation on body weight in diet-induced obese rats. Obes. Surg. 30(3), 948–956 (2020).
Pavlov, V. A. & Tracey, K. J. The vagus nerve and the inflammatory reflex–linking immunity and metabolism. Nat. Rev. Endocrinol. 8(12), 743–754 (2012).
Pelot, N. A. & Grill, W. M. Effects of vagal neuromodulation on feeding behavior. Brain Res. 1693(Pt B), 180–187 (2018).
Li, H. et al. Effects and mechanisms of auricular vagus nerve stimulation on high-fat-diet-induced obese rats. Nutrition 32(1), 156 (2016).
Wang, S. et al. Transcutaneous vagus nerve stimulation induces tidal melatonin secretion and has an antidiabetic effect in Zucker fatty rats. PLoS ONE 10(4), e0124195 (2015).
Yu, Y. et al. Transcutaneous auricular vagal nerve stimulation inhibits limbic-regional P2X7R expression and reverses depressive-like behaviors in Zucker diabetic fatty rats. Neurosci. Lett. 775, 136562 (2022).
Yu, Y. et al. Transcutaneous auricular vagal nerve stimulation inhibits hypothalamic P2Y1R expression and attenuates weight gain without decreasing food intake in Zucker diabetic fatty rats. Sci. Prog. 104(2), 368504211009669 (2021).
Burnstock, G. & Gentile, D. The involvement of purinergic signalling in obesity. Purinergic Signal 14(2), 97–108 (2018).
Obst, M. A. et al. Five weeks of intermittent transcutaneous vagus nerve stimulation shape neural networks: A machine learning approach. Brain Imaging Behav. 16(3), 1217–1233 (2022).
Bannigida, D. M., Nayak, B. S. & Vijayaraghavan, R. Insulin resistance and oxidative marker in women with PCOS. Arch. Physiol. Biochem. 126(2), 183–186 (2020).
Garg, D. & Tal, R. Inositol treatment and ART outcomes in women with PCOS. Int. J. Endocrinol. 2016, 1979654 (2016).
Sørensen, A. E. et al. MicroRNAs related to androgen metabolism and polycystic ovary syndrome. Chem. Biol. Interact. 259(Pt A), 8–16 (2016).
Persson, S. et al. Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome. Fertil. Steril. 116(3), 862–871 (2021).
Duleba, A. J. & Dokras, A. Is PCOS an inflammatory process?. Fertil. Steril. 97(1), 7–12 (2012).
Pani, A. et al. From prediabetes to type 2 diabetes mellitus in women with polycystic ovary syndrome: Lifestyle and pharmacological management. Int. J. Endocrinol. 2020, 6276187 (2020).
Bahadur, A. et al. Comparison of clinical, metabolic and hormonal effects of metformin versus combined therapy of metformin with myoinositol plus D-chiro-inositol in women with polycystic ovary syndrome (PCOS): A randomized controlled trial. Cureus 13(6), e15510 (2021).
Waise, T. M. Z., Dranse, H. J. & Lam, T. K. T. The metabolic role of vagal afferent innervation. Nat. Rev. Gastroenterol. Hepatol. 15(10), 625–636 (2018).
Teff, K. L. Visceral nerves: Vagal and sympathetic innervation. JPEN J. Parenter. Enteral. Nutr. 32(5), 569–571 (2008).
Lundqvist Martin, H. et al. Altered hormonal and autonomic nerve responses to hypo- and hyperglycaemia are found in overweight and insulin-resistant individuals and may contribute to the development of type 2 diabetes. Diabetologia 64(3), 641–655 (2021).
Poon, A. K. et al. Insulin resistance and reduced cardiac autonomic function in older adults: The Atherosclerosis Risk in Communities study. BMC Cardiovasc. Disord. 20(1), 217 (2020).
Isao, S. et al. Low heart rate variability and sympathetic dominance modifies the association between insulin resistance and metabolic syndrome—The toon health study. Circ. J. 81(10), 1447–1453 (2017).
Chen Daniel, L. T. et al. Muscle sympathetic nerve activity is associated with liver insulin sensitivity in obese non-diabetic men. Front. Physiol. 8, 101 (2017).
Licht, C. M. et al. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J. Clin. Endocrinol. Metab. 95(5), 2458–2466 (2010).
Carnethon, M. R. et al. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: The Atherosclerosis Risk In Communities study, 1987–1998. Circulation 107(17), 2190–2195 (2003).
Titikorn, C. et al. Vagus nerve stimulation exerts the neuroprotective effects in obese-insulin resistant rats, leading to the improvement of cognitive function. Sci. Rep. 6, 26866 (2016).
Charles-Henri, M. et al. Obesity-associated alterations in glucose metabolism are reversed by chronic ilbateral stimulation of the abdominal vagus nerve. Diabetes 66(4), 848–857 (2017).
Huang, F. et al. Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: A pilot randomized study. BMC Complement Altern. Med. 14, 203 (2014).
Payne, S. C. et al. Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model. Physiol. Rep. 10(8), e15257 (2022).
Meyers, E. E. et al. Contrasting effects of afferent and efferent vagal nerve stimulation on insulin secretion and blood glucose regulation. Physiol. Rep. 4(4), e12718 (2016).
Jielin, D. et al. Activation of α7nAChR via vagus nerve prevents obesity-induced insulin resistance via suppressing endoplasmic reticulum stress-induced inflammation in Kupffer cells. Med. Hypotheses. 140, 109671 (2020).
Li, S. et al. Therapeutic effect of vagus nerve stimulation on depressive-like behavior, hyperglycemia and insulin receptor expression in Zucker fatty rats. PLoS ONE 9(11), e112066 (2014).
Yin, J. et al. Vagal nerve stimulation for glycemic control in a rodent model of type 2 diabetes. Obes. Surg. 29(9), 2869–2877 (2019).
Kelly, C. C. et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 86(6), 2453–2455 (2001).
Rudnicka, E. et al. Chronic low grade inflammation in pathogenesis of PCOS. Int. J. Mol. Sci. 22(7), 3789 (2021).
González, F. Nutrient-induced inflammation in polycystic ovary syndrome: Role in the development of metabolic aberration and ovarian dysfunction. Semin. Reprod. Med. 33(4), 276–286 (2015).
Tersigni, C. et al. Abnormal uterine inflammation in obstetric syndromes: Molecular insights into the role of chemokine decoy receptor D6 and inflammasome NLRP3. Mol. Hum. Reprod. 26(2), 111–121 (2020).
Maier, S. F. et al. The role of the vagus nerve in cytokine-to-brain communication. Ann. N. Y. Acad. Sci. 840, 289–300 (1998).
Bonaz, B., Sinniger, V. & Pellissier, S. Anti-inflammatory properties of the vagus nerve: Potential therapeutic implications of vagus nerve stimulation. J. Physiol. 594(20), 5781–5790 (2016).
Salama, M., Akan, A. & Mueller, M. R. Transcutaneous stimulation of auricular branch of the vagus nerve attenuates the acute inflammatory response after lung lobectomy. World J. Surg. 44(9), 3167–3174 (2020).
Hong, G. S. et al. Non-invasive transcutaneous auricular vagus nerve stimulation prevents postoperative ileus and endotoxemia in mice. Neurogastroenterol. Motil. 31(3), e13501 (2019).
Zhao, Y. X. et al. Transcutaneous auricular vagus nerve stimulation protects endotoxemic rat from lipopolysaccharide-induced inflammation. Evid. Based Complement Alternat. Med. 2012, 627023 (2012).
Zhao, X. et al. Exploration of the relationship between gut microbiota and polycystic ovary syndrome (PCOS): A review. Geburtshilfe Frauenheilkd 80(2), 161–171 (2020).
Insenser, M. et al. Gut microbiota and the polycystic ovary syndrome: Influence of sex, sex hormones, and obesity. J. Clin. Endocrinol. Metab. 103(7), 2552–2562 (2018).
Lindheim, L. et al. Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): A pilot study. PLoS ONE 12(1), e0168390 (2017).
Zhang, D., Zhang, L. & Yue, F. Serum zonulin is elevated in women with polycystic ovary syndrome and correlates with insulin resistance and severity of anovulation. Eur. J. Endocrinol. 172(1), 29–36 (2015).
Liang, Y. et al. Gut microbiota dysbiosis in polycystic ovary syndrome: Association with obesity—a preliminary report. Can. J. Physiol. Pharmacol. 98(11), 803–809 (2020).
Zhou, L. et al. Correlation between fecal metabolomics and gut microbiota in obesity and polycystic ovary syndrome. Front. Endocrinol. 11, 628 (2020).
Torres, P. J. et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with Hyperandrogenism. J. Clin. Endocrinol. Metab. 103(4), 1502–1511 (2018).
Bonaz, B., Bazin, T. & Pellissier, S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front. Neurosci. 12, 49 (2018).
Grewal, S. & Gupta, V. Effect of obesity on autonomic nervous system. Int. J. Curr. Bio Med. Sci. 1(1), 15–18 (2011).
Eisenstein, M. Microbiome: Bacterial broadband. Nature 533(7603), S104–S106 (2016).
Tse, J. K. Y. Gut microbiota, nitric oxide, and microglia as prerequisites for neurodegenerative disorders. ACS Chem Neurosci. 8(7), 1438–1447 (2017).
Willman, J. et al. Gut microbiome and neurosurgery: Implications for treatment. Clin. Transl. Discov. 2(4), e139 (2022).
Jakob, M. O., Murugan, S. & Klose, C. S. N. Neuro-immune circuits regulate immune responses in tissues and organ homeostasis. Front. Immunol. 11, 308 (2020).
Haney, M. M., Ericsson, A. C. & Lever, T. E. Effects of intraoperative vagal nerve stimulation on the gastrointestinal microbiome in a mouse model of amyotrophic lateral sclerosis. Comp. Med. 68(6), 452–460 (2018).
Aziz, M. et al. Polycystic ovary syndrome: Cardiovascular risk factors according to specific phenotypes. Acta Obstet. Gynecol. Scand. 94(10), 1082–1089 (2015).
Hudecova, M. et al. Endothelial function in patients with polycystic ovary syndrome: A long-term follow-up study. Fertil. Steril. 94(7), 2654–2658 (2010).
Schmidt, J. et al. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: A 21-year controlled follow-up study. J. Clin. Endocrinol. Metab. 96(12), 3794–3803 (2011).
Mani, H. et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: A 20-year retrospective cohort study. Clin. Endocrinol. 78(6), 926–934 (2013).
Papadakis, G. et al. Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinol. 42(4), 340–355 (2017).
Christakou, C. & Diamanti-Kandarakis, E. Structural, biochemical and non-traditional cardiovascular risk markers in PCOS. Curr. Pharm. Des. 19(32), 5764–5774 (2013).
Wild, R. A. et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95(5), 2038–2049 (2010).
Hadaya, J. & Ardell, J. L. Autonomic modulation for cardiovascular disease. Front Physiol. 11, 617459 (2020).
Grassi, G., Seravalle, G. & Mancia, G. Sympathetic activation in cardiovascular disease: Evidence, clinical impact and therapeutic implications. Eur. J. Clin. Invest. 45(12), 1367–1375 (2015).
Thayer, J. F., Yamamoto, S. S. & Brosschot, J. F. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int. J. Cardiol. 141(2), 122–131 (2010).
Sclocco, R., Garcia, R. G., Gabriel, A. et al. Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) effects on autonomic outflow in hypertension. InAnnual International Conference of the IEEE Engineering in Medicine and Biology Society 3130–3133 (2017).
Tran, N. et al. Autonomic neuromodulation acutely ameliorates left ventricular strain in humans. J. Cardiovasc. Transl. Res. 12(3), 221–230 (2019).
Stavrakis, S. et al. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. J. Am. Coll. Cardiol. 65(9), 867–875 (2015).
Stavrakis, S. et al. TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A randomized clinical trial. JACC Clin. Electrophysiol. 6(3), 282–291 (2020).
Almis, H. et al. Self-concept, depression, and anxiety levels of adolescents with polycystic ovary syndrome. J. Pediatr. Adolesc. Gynecol. 34(3), 311–316 (2021).
Harnod, T. et al. Association between depression risk and polycystic ovarian syndrome in young women: A retrospective nationwide population-based cohort study (1998–2013). Hum. Reprod. 34(9), 1830–1837 (2019).
Alur-Gupta, S. et al. Body-image distress is increased in women with polycystic ovary syndrome and mediates depression and anxiety. Fertil. Steril. 112(5), 930-938.e1 (2019).
Cooney, L. G. et al. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: A systematic review and meta-analysis. Hum. Reprod. 32(5), 1075–1091 (2017).
Ethirajulu, A. et al. Insulin resistance, hyperandrogenism, and its associated symptoms are the precipitating factors for depression in women with polycystic ovarian syndrome. Cureus 13(9), e18013 (2021).
Kolhe, J. V. et al. PCOS and depression: Common links and potential targets. Reprod. Sci. https://doi.org/10.1007/s43032-021-00765-2 (2021).
Teede, H. J. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 110(3), 364–379 (2018).
George, M. S. et al. A one-year comparison of vagus nerve stimulation with treatment as usualfor treatment-resistant depression. Biol. Psychiatry 58(5), 364–373 (2005).
Rush, A. J. et al. Vagus nerve stimulation for treatment-resistant depression: A randomized, controlled acute phase trial. Biol. Psychiatry 58(5), 347–354 (2005).
Rush, A. J. et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: A naturalistic study. Biol. Psychiatry 58(5), 355–363 (2005).
Akhtar, H. et al. Therapeutic efficacy of neurostimulation for depression: Techniques, current modalities, and future challenges. Neurosci. Bull. 32(1), 115–126 (2016).
Kennedy, S. H. et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacol. Treat. Can. J. Psychiatry 61(9), 540–560 (2016).
Toffa, D. H. et al. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: A critical review. Seizure 83, 104–123 (2020).
Li, S. et al. Transcutaneous auricular vagus nerve stimulation triggers melatonin secretion and is antidepressive in Zucker diabetic fatty rats. PLoS ONE 9(10), e111100 (2014).
Li, S. et al. Transcutaneous auricular vagus nerve stimulation at 20 Hz improves depression-like behaviors and down-regulates the hyperactivity of HPA axis in chronic unpredictable mild stress model rats. Front. Neurosci. 14, 680 (2020).
Guo, X. et al. Effects of transcutaneous auricular vagus nerve stimulation on peripheral and central tumor necrosis factor alpha in rats with depression-chronic somatic pain comorbidity. Neural Plast. 2020, 8885729 (2020).
Wu, C. et al. Transcutaneous auricular vagus nerve stimulation in treating major depressive disorder: A systematic review and meta-analysis. Medicine 97(52), e13845 (2018).
Kong, J. et al. Treating depression with transcutaneous auricular vagus nerve stimulation: State of the art and future perspectives. Front. Psychiatry 9, 20 (2018).